Accepted at 9:32 a.m. May, 17, 2024 by beejumm
Author: beejumm
Related Note: 1578183592464
Rationale for change

current structure makes it unclear what is the antagonist

Extra was not edited when aromatase inhibitors was added (see history)

Extra Extra
Text
Women who are at increased risk for breast cancer and low risk for adverse medication effects should receive:

{{c1::Tamoxifen, raloxifene, or aromatase inhibitors::3 options}}
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Empty field
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
OME

Additional Resources
One by one
Empty field
#AK_Step1_v12::#AMBOSS::j4a_Qk #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::08_Principles_of_Oncology_and_Therapeutics::11_Cell_Cycle_Independent_Drug_Targets !AK_UpdateTags::^temporary::ImageFix::22::done #AK_Step2_v12::#Subjects::Obstetrics_&_Gynecology::01_Gynecology::Breast::Breast_Cancer::Management AnkiHub_ImageReady::Extra #AK_Step1_v12::#Bootcamp::Pathology::02_Cellular_Injury_&_Neoplasia::11_Cell_Cycle_Independent_Drug_Targets #AK_Step2_v12::#B&B::11_ObGyn::03_Breast::02_Breast_Cancer #AK_Original_Decks::Step_2::Cheesy_Dorian_(M3) #AK_Step2_v12::#OME_banner #AK_Step2_v12::#Subjects::Obstetrics_&_Gynecology::01_Gynecology::Breast::Breast_Cancer !AK_UpdateTags::Step2decks::Cheesy-Dorian-(M3)::Family-Medicine::2-USPSTF-Guidelines !AK_UpdateTags::Table::SERMs #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::05_Sex_Hormones::01_SERMs_&_Aromatase_Inhibitors AnkiHub_ImageReady::Text #AK_Step2_v12::#Resources_by_rotation::FM::uspstf_guidelines #AK_Step2_v12::!Shelf::#Cards_AnKing_Did::4fm #AK_Step2_v12::!Shelf::FM::no_dupes #AK_Step2_v12::Original_decks::Dorian::fam::uspstf_guidelines #AK_Step2_v12::!Shelf::FM::no_dupes::only_step2 #AK_Step1_v12::#Bootcamp::Reproduction::06_Pharmacology::02_Selective_Estrogen_Receptor_Modulators